Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Offers affordable, high-quality solutions for diabetes care
Plans underway to expand screening capacity by 50% for greater accessibility
Cancer cases in India estimated to reach 1.57 million in 2025
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Our Q3 FY25 revenue was at Rs. 1,384.1 crore with an EBITDA of Rs. 360 crore resulting in a 26% EBITDA margin
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Subscribe To Our Newsletter & Stay Updated